|
1,720
|
| 12904 |
NR0B2
|
|
interacts (colocalizes) with
|
NEUROD1
|
|
| 12905 |
NR0B2
|
NOT |
interacts (colocalizes) with
|
TCF3
|
|
| 12906 |
NR0B2
|
|
decreases_activity of
|
NEUROD1
|
by competing with p300 for the BETA2/NeuroD interaction
|
|
14752053
|
Neurological
|
|
3,613
|
| 34085 |
Taurocholate
|
|
increases_expression of
|
NR0B2
|
in liver
|
| 34097 |
Phosphatidylinositol 3-kinase
|
|
affects_expression of
|
NR0B2
|
in liver
|
| 34098 |
PRKCZ
|
|
affects_expression of
|
NR0B2
|
in liver
|
|
20305288
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,615
|
| 34142 |
Cholic acid
|
NOT |
affects_expression of
|
NR0B2
|
in brown adipose tissue
|
| 34143 |
Cholic acid
|
|
increases_expression of
|
NR0B2
|
in liver
|
|
16400329
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
3,617
|
| 34186 |
Colestimide
|
|
decreases_expression of
|
NR0B2
|
in liver
|
| 34204 |
Cholic acid
|
|
increases_expression of
|
NR0B2
|
in liver
|
|
22952571
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,632
|
| 34420 |
NR1H4
|
|
increases_expression of
|
NR0B2
|
|
|
21431855
|
Diabetes mellitus, type II
Obesity
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
4,727
|
| 46804 |
TXNIP
|
|
interacts (colocalizes) with
|
NR0B2
|
in liver
|
|
24037087
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,825
|
| 55017 |
NR5A2
|
|
affects_expression of
|
NR0B2
|
in pancreas
|
|
21852532
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,456
|
| 61198 |
AMPK
|
|
increases_activity of
|
NR0B2
|
|
| 61202 |
NR0B2
|
|
decreases_activity of
|
gluconeogenesis
|
via decreased CREB1 activity
|
| 61205 |
NR0B2
|
|
decreases_activity of
|
CREB1
|
|
|
22117616
|
Diabetes mellitus, type II
Cancer
Insulin resistance
|
|
6,501
|
| 61766 |
Metformin
|
|
increases_expression of
|
NR0B2
|
|
| 61767 |
AMPK
|
|
increases_expression of
|
NR0B2
|
|
| 61768 |
NR0B2
|
|
decreases_activity of
|
gluconeogenesis
|
|
| 61769 |
NR0B2
|
|
decreases_expression of
|
PCK1
|
|
| 61771 |
NR0B2
|
|
decreases_expression of
|
G6PC
|
|
|
17909097
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,607
|
| 63777 |
NR1H4
|
|
affects_expression of
|
NR0B2
|
in liver
|
| 63778 |
NR0B2
|
|
decreases_expression of
|
CYP7A1
|
in liver
|
| 63792 |
NR0B2
|
|
decreases_expression of
|
HNF4A
|
in liver
|
|
26579438
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,617
|
| 63066 |
Metformin
|
|
decreases_expression of
|
NR0B2
|
|
|
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,710
|
| 64831 |
NR0B2
|
|
affects_expression of
|
PPARGC1A
|
in liver
|
| 64832 |
NR0B2
|
|
decreases_expression of
|
NPAS2
|
in liver
|
| 64833 |
NR0B2
|
|
affects_expression of
|
RORA
|
in liver
|
| 64834 |
NR0B2
|
|
affects_expression of
|
RORC
|
in liver
|
| 64835 |
NPAS2
|
|
affects_expression of
|
NR0B2
|
in liver
|
|
25212631
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,721
|
| 64959 |
NR1D1
|
|
affects_expression of
|
NR0B2
|
|
|
22841001
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,415
|
| 73006 |
APOE KO mouse
|
|
increases_expression of
|
NR0B2
|
in liver; 2.03 fold, when fed with 1.25% cholesterol;
|
| 73189 |
NR0B2
|
|
increases_activity of
|
NR1H4-NR0B2-SREBF1c regulatory cascade
|
|
| 73192 |
NR0B2
|
|
decreases_activity of
|
SREBF1c
|
SHP is expressed in a wide variety of tissues, including heart, brain, liver;
|
|
21857965
|
Alzheimer disease
Metabolic
|
|
7,526
|
| 74219 |
NR0B2
|
|
interacts (colocalizes) with
|
HNF4A
|
|
| 74230 |
Bile salt
|
|
increases_activity of
|
NR0B2
|
in hepatocytes
|
| 74231 |
NR1H4
|
|
increases_expression of
|
NR0B2
|
in hepatocytes
|
| 74232 |
NR0B2
|
|
decreases_activity of
|
HNF4A
|
|
| 74233 |
NR0B2
|
|
decreases_activity of
|
NR5A2
|
|
| 74234 |
NR0B2
|
|
interacts (colocalizes) with
|
NR5A2
|
|
| 75322 |
NR1H4
|
|
increases_activity of
|
NR0B2
|
in hepatocytes
|
| 75335 |
NR0B2
|
|
decreases_activity of
|
SLC10A1
|
at the basolateral membrane of hepatocytes,; via repressing the transactivation of NTCP by retinoic acid receptor and HNF4alpha
|
| 75399 |
NR0B2
|
|
affects_activity of
|
bile acid biosynthetic process
|
|
| 75489 |
NR0B2
|
|
decreases_activity of
|
CREB1
|
concerning the transactivating activity of CREB when it is fasting-induced,
|
| 75491 |
NR0B2
|
|
decreases_activity of
|
FOXO1
|
concerning the transactivating activity of FOXO1;
|
| 75493 |
NR0B2
|
|
decreases_activity of
|
CEBP
|
|
| 75494 |
NR0B2
|
|
decreases_activity of
|
NR3C1
|
|
| 75495 |
NR0B2
|
|
decreases_activity of
|
FOXM1
|
HNF3 not found in cited paper !
|
|
25073467
|
Gastrointestinal
Metabolic
|
|
7,627
|
| 76388 |
NR1H4
|
|
increases_expression of
|
NR0B2
|
in cultured mouse neurons and in mouse brain tissues; if FXR is activated;
|
|
27545319
|
Metabolic
|
|
7,631
|
| 76345 |
NR0B2
|
|
increases_ubiquitination/sumoylation of
|
NR1H3
|
in astrocytes, but not in macrophages; thus facilitating the anti-inflammatory actions of LXRs;
|
| 76346 |
NR0B2
|
|
increases_ubiquitination/sumoylation of
|
NR1H2
|
in astrocytes, but not in macrophages; thus facilitating the anti-inflammatory actions of LXRs;
|
| 76350 |
NR0B2
|
|
increases_activity of
|
PIAS1
|
|
| 76353 |
NR0B2
|
|
decreases_quantity of
|
SIAH1-PIAS1 complex
|
via disrupting the interaction of PIAS1 with the E3 ubiquitin ligase SIAH1;
|
| 76357 |
NR0B2
|
|
interacts (colocalizes) with
|
PIAS1
|
hereby stabilizing the E3 SUMO ligase PIAS1;
|
|
27485016
|
Metabolic
Inflammation
|
|
8,624
|
| 89131 |
NR1H4
|
|
increases_expression of
|
NR0B2
|
in liver
|
| 89132 |
NR0B2
|
|
affects_activity of
|
NR5A2
|
in liver
|
|
27320064
|
Gastrointestinal
Metabolic
|
|
9,153
|
| 96952 |
AIMD mouse
|
|
increases_expression of
|
NR0B2
|
in liver
|
| 96954 |
NR0B2
|
|
decreases_activity of
|
CYP7A1
|
|
|
30030441
|
Gastrointestinal
Metabolic
|
|
10,797
|
| 109833 |
NR0B2
|
|
decreases_activity of
|
gluconeogenesis
|
in primary hepatocytes and in liver cell lines ; via inhibiting the expression of hepatic gluconeogenic genes
|
|
25073467
|
Metabolic
|
|
13,997
|
| 132201 |
NR0B2
|
|
affects_activity of
|
Diabetes mellitus, type II
|
|
| 132202 |
hyperglycemia
|
|
increases_expression of
|
NR0B2
|
|
| 132203 |
NR0B2
|
|
decreases_expression of
|
INS
|
via NEUROD1 and PDX1
|
| 132204 |
NR0B2
|
|
decreases_activity of
|
NEUROD1
|
|
| 132205 |
NR0B2
|
|
decreases_activity of
|
PDX1
|
|
|
30793219
|
MODY, type VI
Ciliopathy
|
CIDeRplus